Clinical data for the five patients with a long delay between the onset of the neuropathy and the discovery of the tumour who had no anti-onconeural antibodies (group IIB)
| No | Sex/age | Delay (y) | Clinical manifestations | Course | Rankin | Electrophysiology | CSF | Tumour | Pathological study |
|---|---|---|---|---|---|---|---|---|---|
| 22 | 2M/73 | 5 | Sensory loss in lower limbs, lower limbs areflexia | Progressive | 2 | Axonal, reduced/absent SAP, reduced MAP, mild reduction of CV | 0.8 g/l 1 lympho | Prostate adenocarcinoma | Nerve biopsy: fibre loss, no inflammatory changes |
| 23 | F/71 | 9 | Pain, paresthesia, sensory loss and areflexia in lower limbs | Progressive | 1 | Axonal, reduced MAP/SAP. Mild reduction of CV | 0.2 g/l 1 lympho | Pancreas adenocarcinoma | Fibre loss, regenerating clusters, no inflammatory changes |
| 24 | M/72 | 4-5 | Distal sensory motor deficit and areflexia in lower limbs | Progressive | 2 | Axonal, reduced/absent SAP and MAP, mild reduction M-S CV | 0.67 g/l 1 lympho | Penis epithelioma | Nerve biopsy: severe fibre loss, no inflammatory changes |
| 25 | M/64 | 14 | Sensory motor distal deficit and areflexia in lower limbs | Progressive | 2 | Axonal, reduced MAP/SAP, mild reduction of CV | 0.7 g/l 1 lympho | Prostate adenocarcinoma | ND |
| 26 | M/64 | 10 | CIDP. Mild paraesthesia and motor deficit, hyporeflexia in four limbs. Hypertrophic nerves. MGUS IgG | Progressive | 1 | Demyelinating severely reduced MCV, temporal dispersion | 8.2 g/l 1 lympho | Malignant melanoma | Nerve biopsy: demyelinated fibres, onion bulb formations |
Abbreviations are the same as in table 2. In all cases, the neuropathy preceded the diagnosis of cancer.